In the most recent of a series of four studies featured in Bone Marrow Transplantation, researchers have found that a highly sensitive DNA-based test can help doctors predict which patients with acute myeloid leukemia (AML) are most likely to relapse.

Cambridge, MA, February 17, 2025 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies. The initiative builds on MSK’s global leadership in this field under the direction of Yelena Y. Janjigian, MD, Carroll and Milton Petrie Chair; Chief, GI Oncology; and Founding Director of the MSK GEC Therapeutics Accelerator, whose group has delivered multiple practice-changing advances in gastric and gastroesophageal junction cancers. Patrick Evans, BS, MBA, Senior Project Manager in the Janjigian Lab, will serve as the MSK project lead, supporting integration of scientific, operational, and translational efforts across teams.

St. Jude Children’s Research Hospital scientists and multinational collaborators created AI-powered M-PACT to facilitate next-generation classification of pediatric brain tumors by liquid biopsy.